Top Buy Stocks
Sign In
NASDAQ:ESPR
Esperion Therapeutics Stock News
Invest in ESPR
$1.17
-0.0300 (-2.50%)
At Close: Jun 13, 2025
Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?
07:03am, Saturday, 14'th Jun 2025
Esperion's recent rebound is driven by stronger-than-expected prescription growth, revived business momentum after Medicare coverage issues subsided, and good news flow from investor conferences. Mana
Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?
12:37pm, Thursday, 05'th Jun 2025
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limite
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference
08:00am, Friday, 09'th May 2025
ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Confer
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Thursday, 08'th May 2025
ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion
– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Brin
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
01:10pm, Wednesday, 07'th May 2025
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year.
Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript
10:49am, Tuesday, 06'th May 2025
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Ch
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
08:15am, Tuesday, 06'th May 2025
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.34 per share a year ago.
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
11:06am, Tuesday, 29'th Apr 2025
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion to Participate in The Citizens Life Sciences Conference
08:00am, Friday, 25'th Apr 2025
ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, a
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
10:35am, Wednesday, 23'rd Apr 2025
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Tuesday, 22'nd Apr 2025
Esperion Therapeutics (ESPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
08:00am, Thursday, 10'th Apr 2025
Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology
Esperion Appoints Robert E. Hoffman to Board of Directors
08:00am, Tuesday, 01'st Apr 2025
- Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Rob
